Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar Belakang: Kanker pankreas merupakan penyakit dengan kesintasan rendah dan kesulitan untuk melakukan diagnosis. Pemeriksaan Computed Tomography (CT)-Scan abdomen dan Ca 19-9 merupakan modalitas yang murah, mudah, dan terjangkau dalam diagnosis kanker pankreas. Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA) merupakan pemeriksaan baku emas untuk diagnosis kanker pankreas tetapi belum banyak tersedia di fasilitas kesehatan di IndonesiaTujuan: Penelitian ini bertujuan untuk mengetahui kemampuan diagnostik CT-Scan abdomen dan Ca 19-9 dibandingkan dengan EUS-FNA dalam diagnosis kanker pankreas.Metode: Desain studi ini adalah potong lintang dengan melihat rekam medis 62 pasien dengan kecurigaan kanker pankreas di RSCM pada tahun 2015-2019. Diambil pasien-pasien yang memiliki data Ca 19-9 dan CT-Scan abdomen yang kemudian dilakukan EUS-FNA untuk penegakan diagnosis kanker pankreas.Hasil: Sensitivitas dan spesifisitas CT-Scan abdomen masing-masing 76,27% dan 100%, sedangkan Ca 19-9 masing-masing 67,8% dan 33,33%. Nilai duga positif (NDP), nilai duga negatif (NDN), rasio kemungkinan positif (RKP), rasio kemungkinan negatif (RKN), dan akurasi CT-Scan abdomen masing-masing adalah 100%, 17.65%, tidak dapat dinilai, 0,24 , dan 77,42%. Nilai duga positif, NDN, RKP, RKN, dan akurasi untuk Ca 19-9 masing-masing adalah 95.24%, 5%, 1,02, 0,97, dan 66,13%.Kesimpulan: Kombinasi pemeriksaan CT-Scan Abdomen dan Ca 19-9 memiliki sensitivitas yang tinggi untuk kanker pankreas. Computed Tomography abdomen dapat digunakan untuk diagnosis kanker pankreas dengan sensitivitas dan spesifisitas yang baik.

---

Introduction: Pancreatic cancer is a disease with low survival rate and difficult to diagnose. Abdominal computed tomography (CT) and Ca 19-9 are diagnostic modalities which are easy, simple, and non-invasive in diagnosis of pancreatic cancer. Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA) is the gold standard for diagnosis of pancreatic cancer but it is not available in many health care facilities in Indonesia.Purpose: This study aims to know the diagnostic accuracy of abdominal CT and Ca 19-9 compared to EUS-FNA for diagnosis of pancreatic cancer.Methods: The design of this study is cross-sectional by searching medical record of 62 patients with clinical suspicion of pancreatic cancer in Cipto Mangunkusumo hospital from year 2015-2019. Patients who undergo EUS-FNA with clinical suspicion of pancreatic cancer and have abdominal CT and Ca 19-9 data is included.Results: The sensitivity and specificity of abdominal CT are 76.27% and 100%, respectively, and Ca 19-9 are 67.8% and 33.33%, respectively. Positive predictive value, NPV, positive likelihood ratio, negative likelihood ratio, and accuracy of abdominal CT are 100%, 17.65%, unmeasurable, 0.24 , and 77.42%, respectively. Positive predictive value, NPV, positive likelihood ratio, negative likelihood ratio, and accuracy of Ca 19-9 are 95.24%, 5%, 1.02, 0.97, and 66.13%, respectively.Conclusion: The combined sensitivity of abdominal CT and Ca 19-9 has high sensitivity to diagnose pancreatic cancer. Abdominal CT can be used to diagnose pancreatic cancer with good sensitivity and specificity."

"Latar Belakang : Tingkat akurasi EUS FNA dalam diagnosis lesi pankreas diduga dipengaruhi oleh berbagai macam faktor. Penelitian mengenai faktor yang mempengaruhi keberhasilan EUS FNA belum pernah dilakukan di Indonesia. Penelitian ini dilakukan untuk mengetahui faktor-faktor yang mempengaruhi keberhasilan EUS FNA untuk diagnosis lesi pankreas pada populasi Indonesia.Metode : Penelitian ini merupakan studi potong lintang dari data rekam medis pada januari 2012-Juli 2022 atau total seluruh subjek yang dilakukan EUS FNA karena lesi pankreas di PESC RSCM. Pasien dengan data tidak lengkap dan lesi peripankreas tidak diikutkan. Karakteristik dasar subjek penelitian ditampilkan dalam bentuk tabel. Analisis bivariat menggunakan uji chi square dilakukan dengan masing-masing variabel bebas terhadap keberhasilan diagnostik EUS FNA untuk menghitung nilai odds ratio (OR). Variabel dengan nilai p< 0,25 pada analisa bivariat dimasukkan ke analisa multivariat dengan regresi logistik.Hasil : Sebanyak 201 pasien dengan lesi pankreas yang menjalani pemeriksaan EUS FNA diikutkan dalam penelitian. Angka keberhasilan diagnostik EUS FNA pada lesi pankreas adalah sebesar 77,11%. Ukuran lesi ³3 cm diasoasikan dengan peningkatan keberhasilan diagnosis EUS FNA berdasarkan analisis bivariat (OR 2,46; IK95 1,25-4,86; p= 0,008). Analisis multivariat menunjukan bahwa ukuran lesi ³3 cm (OR 18,95; IK95 4,77-75,29; p = 0,000),  lokasi lesi di korpus (OR 2.82; IK95 1.03-7.77; p= 0,04) dan ukuran jarum 22G (OR 7.49; IK95 1.87-29.97; p= 0.004) diasoasikan dengan peningkatan keberhasilan diagnosis. Kesimpulan : Ukuran lesi, lokasi lesi dan ukuran jarum, merupakan faktor yang mempengaruhi keberhasilan diagnostik EUS FNA pada lesi pankreas.

---

Background: Diagnostic accuracy of EUS FNA in diagnosing pancreatic lesion are affected by several factors. Clinical study regarding these factors had not been done in Indonesia. This study aims to study factors affecting the diagnostic yield of EUS FNA in diagnosing pancreatic lesion in Indonesian population. 

Method: This study is a cross-sectional study of medical record data in January 2012-July 2022 or a total of all subjects who underwent EUS FNA due to pancreatic lesions at PESC RSCM. Patient with incomplete data and peripacreatic lesion was excluded. Clinical characteristics of sample is presented in a table. Bivariat analysis was conducted with chi square test between independent factors and diagnostic success of EUS FNA to obtained the odds ratio (OR). Factors with p-value above 0,25 are included for multivariat analysis using logistic regression.  

Result: A total of 201 patients underwent EUS FNA was included in this study. Success rate of diagnosing pancreatic lesion using EUS FNA was 77,11%. Lesion size ³3 cm increased the odds for diagnostic success based on bivariat analysis (OR 2,46; 95% CI 1,25-4,86; p = 0,008). Multivariate analysis showed that the lesion size ³ 3 cm (OR 18.95; CI95 4.77-75.29; p = 0.000), the location of the lesion in the corpus (OR 2.82; CI95 1.03-7.77; p = 0.04) and needle size 22G (OR 7.49; CI95 1.87-29.97; p= 0.004) was associated with an increase in diagnostic yield.

Conclusion: The size of the lesion, the location of the lesion and the size of the needle, are factors that influence the diagnostic yield of EUS FNA in pancreatic lesions"

"Pancreatic carcinoma commonly occur in patients over 60 years. It is usually manifested as abdominal pain, jaundice, and pancreatic mass. In this report, a pancreatic carcinoma occured in young woman is presented. A surgical drainage was done and followed by Whipple resection. However the patient passed away three month after the diagnosis.

---

Karsinoma pankreas umumnya terjadi pada pasien berusia di atas 60 tahun. Biasanya bermanifestasi sebagai perut nyeri, penyakit kuning, dan massa pankreas. Dalam laporan ini, karsinoma pankreas yang terjadi pada wanita muda adalah disajikan. Drainase bedah dilakukan dan diikuti dengan reseksi Whipple. Namun pasien tersebut meninggal hilang tiga bulan setelah diagnosis."

"ABSTRAKTujuan: Menilai ekspresi protein Epidermal Growth Factor Receptor (EGFR) pada Karsinoma Sel Ginjal (KSG) serta kaitannya dengan faktor-faktor prediktor prognosis yang dinilai secara histopatologik (subtipe, staging histopatologik, derajat anaplasia inti Fuhrman)Metode: Studi potong lintang terhadap jaringan yang difiksasi formalin dan diletakkan di dalam parafin dari pasien-pasien dengan KSG, yang diwarnai menggunakan metode imunohistokimia terhadap protein EGFR. Hasil: Ekspresi EGFR pada membran ditemukan pada 46% dari keseluruhan kasus (N=41) dan ekspresi EGFR di sitoplasma ditemukan pada 49% dari keseluruhan kasus (N=41). Terdapat hubungan antara subtipe histopatologik dan derajat anaplasia inti Fuhrman dengan ekspresi EGFR di sitoplasma (nilai p 0,017 dan 0,014 dengan uji Fisher’s exact). Tidak ditemukan asosiasi antara staging histopatologik dengan ekspresi EGFR.Diskusi: Perlu dibuat penelitian lanjutan dengan membandingkan ekspresi EGFR terhadap angka kesintasan pasien serta dibandingkan dengan faktor prediktor prognosis yang lain. Kemaknaan lokasi ekspresi EGFR di sitoplasma juga memerlukan perhatian khusus dan pembuktian secara ilmiah.

---

ABSTRACTObjective: To study the expression of Epidermal Growth Factor Receptor protein in Renal Cell Carcinoma (RCC) and its relationship with prognostic predictor factors evaluated histopathologically (subtype, histopathological staging, Fuhrman nuclear grading). Methods: This was a cross-sectional study on 41 formalin-fixated paraffin-embedded tissue of patients with RCC, stained using immunohistochemical method against EGFR protein. Result: Membranous EGFR expression was found in 46% of cases (N=41), while cytoplasmic EGFR expression was found in 49% of cases. There was a significant association between histopathological subtype or Fuhrman nuclear anaplasia grading and cytoplasmic expression of EGFR (p value 0,017 and 0,014, respectively, using Fisher’s exact test). No significant association was found between histopathological staging and EGFR expressionDiscussion: A further study on the association EGFR expression and survival, and its comparison to other prognostic factors is necessary. The significance of EGFR expresion in the cytoplasm requires special attention and further scientific evidence."

"[ABSTRAKLatar Belakang : Pada kanker pankreas dapat terjadi obstruksi pada duktus pankreatikus yang menghambat transfer enzim dan bikarbonat ke duodenum yang menyebabkan aktifitas enzim tidak cukup adekuat untuk mempertahankan proses pencernaan secara normal yang disebut sebagai pancreatic exocrine insufficiency (PEI), yang dapat dideteksi dengan pemeriksaan kadar fecal elastase 1.Tujuan : Mengetahui proporsi dan derajat PEI, proporsi steatore pada kanker pankreas, perbedaan kadar fecal elastase 1 antara kanker pankreas yang resectable dan unresectable dan perbedaan rerata kadar fecal elastase 1 berdasarkan stadium kanker pankreas.Metode : Penelitian ini adalah studi potong lintang untuk menentukan perbedaan kadar fecal elastase 1 antara kanker pankreas yang resectable dan unresectable. Penelitian ini dilakukan di Rumah Sakit Cipto Mangunkusumo, beberapa rumah sakit jejaring RSCM, dan RS Wahidin Sudirohusodo Makasar dari bulan November 2014 sampai dengan Mei 2015. Uji statistik yang digunakan untuk menilai perbedaan kadar fecal elastase 1 antara kanker pankreas yang resectable dan unresectable adalah Mann Whitney dan untuk menilai perbedaan rerata kadar fecal elastase 1 berdasarkan stadium kanker pankreas adalah Kruskal Wallis.Hasil : Sebanyak 48 subyek kanker pankreas diikutkan dalam penelitian, dengan kategori resectable sebanyak 19(39,6%) subyek, dan 29(60,4%) subyek yang unresectable. Proporsi pasien kanker pankreas yang mengalami PEI sebanyak 75% (IK 95% 0,63-0,87) dan proporsi pasien kanker pankreas yang memberikan gejala steatore sebanyak 68,8% (IK 95% 0,557-0,819). Tidak ada perbedaan kadar fecal elastase 1 yang bermakna (P=0,738) antara kelompok resectable dan unresectable dengan nilai median pada kelompok resectable adalah 38,0(15-500) μg/g dan pada kelompok unresectable adalah 35,0(15-500) μg/g. Tidak ada perbedaan bermakna (p=0,767) kadar fecal elastase 1 berdasarkan stadium kanker pankreas dengan nilai median(rentang) pada stadium IB 36(15-100) μg/g, stadium IIA 62(15-500) μg/g, stadium III 15(15-500) μg/g, dan stadium IV 36(15-500) μg/g.Kesimpulan : Pada penelitian ini didapatkan proporsi PEI dan steatore yang tinggi pada kanker pankreas. Tidak ditemukan perbedaan bermakna kadar fecal elastase 1 antara kanker pankreas yang resectable dan unresectable. Tidak terdapat perbedaan rerata kadar fecal elastase 1 berdasarkan stadium kanker pankreas.

---

ABSTRACTBackground : In the pancreatic cancer can occur obstruction of the pancreatic duct that inhibit the enzyme transfer and bicarbonate into the duodenum which causes the enzyme activity is not quite adequate to maintain normal digestive process referred to as pancreatic exocrine insufficiency (PEI) that can be detected by measurement of fecal elastase 1 level.Objective : Knowing the proportion and the degree of PEI, the steatore proportion in pancreatic cancer, the difference levels of fecal elastase 1 between resectable and unresectable pancreatic cancer and differences between the mean levels of fecal elastase 1 based on the stage of pancreatic cancer.Methods : A cross-sectional study to determine the difference levels of fecal elastase 1 between resectable and unresectable pancreatic cancer. This research was conducted at Cipto Mangunkusumo hospital, some satellite of Cipto Mangunkusumo hospital, and Wahidin Sudirohusodo Makasar hospital at November 2014 until May 2015. The statistical test used to assess differences in the levels of fecal elastase 1 between resectable and unresectable pancreatic cancer is Mann Whitney and to assess the differences between the mean levels of fecal elastase 1 based on staging pancreatic cancer is the Kruskal Wallis.Results : A total of 48 subjects with pancreatic cancer were participated in this study, with resectable category were 19 (39.6%) subjects, and 29 (60.4%) subjects who unresectable. The proportion of patients with pancreatic cancer that experienced PEI are 75% (CI 95% 0.63 - 0.87) and the proportion of patients with pancreatic cancer which provide steatore symptoms are 68.8% (CI 95% 0.557 - 0.819). There is no significant difference levels of fecal elastase 1 (P = 0.738) between the resectable and unresectable where the resectable group median value is 38.0 (15-500) μg / g and in unresectable group was 35.0 (15-500) μg / g. There is no significant difference (p = 0.767) levels of fecal elastase 1 based on the stage of pancreatic cancer with median (range) in stage IB 36 (15-100) pg / g, stage IIA 62 (15-500) pg / g, stage III 15 (15-500) μg / g, and stage IV 36 (15-500) μg / g.Conclusion : This study found a high proportion of PEI and steatore in pancreatic cancer. there is no significant difference fecal elastase 1 levels between the resectable and unresectable pancreatic cancer. There is no significant difference between mean levels of fecal elastase 1 based on the stage of pancreatic cancer., Background : In the pancreatic cancer can occur obstruction of the pancreatic duct that inhibit the enzyme transfer and bicarbonate into the duodenum which causes the enzyme activity is not quite adequate to maintain normal digestive process referred to as pancreatic exocrine insufficiency (PEI) that can be detected by measurement of fecal elastase 1 level.Objective : Knowing the proportion and the degree of PEI, the steatore proportion in pancreatic cancer, the difference levels of fecal elastase 1 between resectable and unresectable pancreatic cancer and differences between the mean levels of fecal elastase 1 based on the stage of pancreatic cancer.Methods : A cross-sectional study to determine the difference levels of fecal elastase 1 between resectable and unresectable pancreatic cancer. This research was conducted at Cipto Mangunkusumo hospital, some satellite of Cipto Mangunkusumo hospital, and Wahidin Sudirohusodo Makasar hospital at November 2014 until May 2015. The statistical test used to assess differences in the levels of fecal elastase 1 between resectable and unresectable pancreatic cancer is Mann Whitney and to assess the differences between the mean levels of fecal elastase 1 based on staging pancreatic cancer is the Kruskal Wallis.Results : A total of 48 subjects with pancreatic cancer were participated in this study, with resectable category were 19 (39.6%) subjects, and 29 (60.4%) subjects who unresectable. The proportion of patients with pancreatic cancer that experienced PEI are 75% (CI 95% 0.63 - 0.87) and the proportion of patients with pancreatic cancer which provide steatore symptoms are 68.8% (CI 95% 0.557 - 0.819). There is no significant difference levels of fecal elastase 1 (P = 0.738) between the resectable and unresectable where the resectable group median value is 38.0 (15-500) μg / g and in unresectable group was 35.0 (15-500) μg / g. There is no significant difference (p = 0.767) levels of fecal elastase 1 based on the stage of pancreatic cancer with median (range) in stage IB 36 (15-100) pg / g, stage IIA 62 (15-500) pg / g, stage III 15 (15-500) μg / g, and stage IV 36 (15-500) μg / g.Conclusion : This study found a high proportion of PEI and steatore in pancreatic cancer. there is no significant difference fecal elastase 1 levels between the resectable and unresectable pancreatic cancer. There is no significant difference between mean levels of fecal elastase 1 based on the stage of pancreatic cancer.]"

"Pendahuluan. Fistula pankreas masih merupakan komplikasi paling sering setelah pankreatikoduodenektomi yang menyebabkan masa rawat lama dan biaya besar.  Fistula ini terjadi sampai 45%.  Kebocoran anastomosis pankreatikojejunostomi merupakan faktor yang paling penting. Belum ada data tentang faktor pankreas yang dapat memengaruhi fistula pankreas di Jakarta, khususnya RS Cipto Mangunkusumo sehingga dilakukan penelitian ini.

Metode.  Penelitian cross sectional ini dilakukan pada 70 orang penderita yang dilakukan pankreatikoduodenektomi. Data dikumpulkan dari data sekunder rekam medis tahun 2016-2019 berupa tekstur pankreas, diameter duktus pankreatikus, teknik anastomosis pankreatikojejunal, dan penggunaan stent pada pankreatikojejunal sebagai variabel bebas. Fistula pankreas sebagai variabel terikat. Data diuji dengan uji Spearman dikarenakan abnormalitas distribusi data.

Hasil.  Didapatkan 70 subjek. Tidak ada kejadian fistula pankreas sebanyak 21,4% dan ada fistula pankreas sebanyak  78,6%. Diameter duktus pankreatikus tidak melebar sebanyak 78,6% dan melebar sebanyak 21,4%. Tekstur pankreas soft sebanyak 22,9% dan hard sebanyak 77,1%. Penggunaan stent sebanyak 21,4% dan tidak ada penggunaan sebanyak 78,6%. Tipe anastomosis pankreatikojejunal dunking atau invaginasi sebanyak 82,9% dan duck to mucosa sebanyak 17,1%.  Faktor risiko yang bermakna pada analisis bivariat adalah diameter duktus pankreatikus (p=0,007). 

Kesimpulan. Penilaian diameter duktus pankreatikus intraoperatif mempunyai hubungan bermakna dalam memperkirakan kejadian fistula pankreas pascaoperasi pankreatikoduodenektomi.

 

---

Introduction. Pancreatic fistula is the most common complication after pancreaticoduodenectomy that cause longer hospital stay and higher cost. It happens 45%. Pancreaticojejunostomy anastomosis leakage is the most important factor. No data about pankreas’ factor that can influence pancreatic fistula in Cipto Mangunkusumo hospital so this study is held.

Method. This cross sectional study was done for 70 patients. Data was collected from medical record in 2016-2019.   The data are pancreatic texture, pancreatic duct diameter, pancreaticojejunal anastomotic technique, and use of  stent in pancreaticojejunal as the independent variables. Pancreatic fistula as the dependent variable.   We analyzed  using Spearman test due to abnormality data distribution.

 

Results. There are 70 subjects enrolled. Subjects with no pancreatic fistula about 21,4% and with pancreatic fistula 78,6%.   No dilated pancreatic duct diameter about 78,6% and dilated about 21,4%. Soft texture pancreas about 22,9% and hard 77,1%. Use of stent about 21,4% and no stent 78,6%. Pancreaticojejunal anastomotic type of dunking or invaginating about 82,9% and duck to mucosa about 17,1%.  The significant risk factor in bivariate analysis is diameter of the pancreatic duct (p=0,007). 

Conclusion. Intraoperative assessment of the pancreatic duct diameter associated significantly in predicting pancreatic fistula after pancreaticoduodenectomy.

 

"

"Latar Belakang: Karsinoma pankreas umumnya merupakan adenokarsinoma duktus dari pankreas, karena lebih dari 90% tumor pankreas berasal dari epitel duktus dan memiliki angka mortalitas tinggi. Adenokarsinoma pankreas menyebabkan berbagai gejala akibat obstruksi duktus biliaris dan duktus pankreatikus serta hipermetabolisme terkait perubahan metabolik pada kanker. Tindakan kuratif meliputi pembedahan menyebabkan perubahan anatomi fisiologik saluran cerna dan dapat menimbulkan berbagai komplikasi gastrointestinal yang menyebabkan malnutrisi pada pasien. Perubahan metabolik, gejala penyakit, dan tatalaksana adenokarsinoma pankreas dapat menyebabkan malnutrisi dan kaheksia kanker. Terapi nutrisi perioperatif yang adekuat akan menghasilkan outome bedah yang baik, menurunkan morbiditas dan mortalitas pascabedah, dan meningkatkan kualitas hidup pasien. Metode: Laporan serial kasus ini menguraikan empat kasus adenokarsinoma pankreas, yaitu dua kasus adenokarsinoma papila Vateri, satu kasus adenokarsinoma papila Vateri yang sudah infiltrasi ke duodenum, dan satu kasus adenokarsinoma pankreas dari kaput sampai kauda. Keempat pasien serial kasus tergolong kaheksia kanker. Pembedahan pada keempat kasus disesuaikan dengan lokasi dan metastasis kanker. Terapi nutrisi pada serial kasus ini dilakukan sesuai dengan pedoman terapi nutrisi perioperatif. Seluruh pasien mendapat terapi nutrisi mulai dari masa prabedah hingga pascabedah dengan pemberian energi dan makronutrien ditingkatkan bertahap sesuai dengan kondisi klinis dan toleransi pasien. Suplementasi mikronutrien juga diberikan kepada keempat pasien. Pemantauan pasien meliputi keluhan subjektif, hemodinamik, analisis dan toleransi asupan, pemeriksaan laboratorium, antropometri, keseimbangan cairan, dan kapasitas fungsional. Hasil: Selama pemantauan di RS, keempat pasien menunjukkan perbaikan klinis, peningkatan toleransi asupan, outcome bedah yang baik, serta perbaikan kapasitas fungsional dan hasil laboratorium. Kesimpulan: Terapi nutrisi perioperatif pada keempat pasien berperan penting dalam menunjang perbaikan klinis, dan outcome bedah, serta mendukung terapi pada kasus kanker pankreas.

---

Background: Pancreatic cancer usually refers to ductal adenocarcinomas of the pancreas, since more than 90% of the tumors are ductal epithelium origin and have high mortality rate. Pancreatic adenocarcinoma causes various symptoms resulted from ductal biliary and pancreatic ducts obstruction, along with hypermetabolism related to metabolic alteration in cancer. Curative management involves surgery will make changes in gastrointestinal anatomy and physiology, and cause various gastrointestinal complication that will lead to malnutrition. Metabolic changes, symptoms of the disease and pancreatic adenocarcinoma therapy will cause malnutrition and cancer cachexia. Adequate perioperative nutrition will have good surgery outcome, reduce postoperative morbidity and mortality and increase patients quality of life.

Methods: This serial case report described four cases of pancreatic adenocarcinoma consist of two cases with adenocarcinoma of the papilla of Vater, one case with adenocarcinoma of the papilla of Vater with duodenum infiltration, and one case with pancreatic adenocarcinoma from head to tail. All patients classified as cancer cachexia. Surgery was carried out corresponds to cancer location and metastasis. Nutrition therapy in this serial case report was conducted in accordance to perioperative nutrition therapy guideline. All patients received nutrition support from preoperative to postoperative with gradual increased of energy and macronutrient adjusted to the clinical condition and food tolerance of the patients. Micronutrients supplementation was given to all patients. Monitoring included patients complaints, hemodynamic, food analysis and intake tolerance, laboratory results, anthropometry, fluid balance and functional capacity.

Results: During monitoring in the hospital, all patients showed improve clinical outcomes, increased food intake tolerance, good surgery outcomes, and improved functional capacity, and laboratory results.

Conclusion: Perioperative nutrition therapy in all patients play an important role in supporting clinical outcome improvement, surgery outcomes, and therapy in pancreatic cancer."

"Inflamasi kronik adalah proses yang penting dalam patofisiologi adenokarsinoma duktal pankreas (PDAC). Beberapa studi telah meneliti potensi enzim siklooksigenase-2 (COX-2) sebagai faktor prognostik PDAC, dengan hasil yang kontradiktif. Nuclear factor kappa−B (NF−?B), specificity protein 1 (Sp1), dan c−Jun adalah faktor transkripsi gen COX2. Penelitian ini adalah studi observasional eksploratori yang bertujuan untuk mengidentifikasi asosiasi ekspresi protein NF−?B (RelA/ p65), COX−2, Sp1, dan c−Jun dengan kesintasan pasien PDAC. Ekspresi protein tersebut dinilai di jaringan pasien PDAC menggunakan metode imunohistokimia. Diidentifikasi ekspresi keempat protein tersebut dengan overall survival (OS) dan karakteristik klinikopatologis pasien PDAC. Sebanyak 53 jaringan PDAC dari biopsi atau reseksi kanker diikutkan dalam penelitian. Hasilnya terdapat korelasi antara keempat protein di jaringan kanker. Ekspresi NF−?B sitoplasmik (aHR = 0.31; 95% CI 0.11–0.90; p = 0.032) atau nuklear (aHR = 0.22; 95% CI 0.07–0.66; p = 0.007) berhubungan secara independen dengan prognosis pasien yang lebih baik. Protein lainnya tidak berhubungan dengan kesintasan pasien. Hal ini menunjukkan bahwa peran inflamasi di PDAC lebih kompleks dari yang diperkirakan sebelumnya.

---

Chronic inflammation is a crucial driver of carcinogenesis in pancreatic ductal adenocarcinoma (PDAC). Several studies have investigated the prognostic significance of cyclooxygenase−2 (COX−2) expression in PDAC patients, obtaining conflicting results. Nuclear factor kappa−B (NF−?B), specificity protein 1 (Sp1), and c−Jun are known as the transcription factors of the COX2 gene. This exploratory observational study investigated the association of the NF−?B, COX−2, Sp1, and c−Jun expressions with patient survival in PDAC. We used the immunohistochemical method to detect the PDAC tissue expressions of NF−?B (RelA/p65), COX−2, Sp1, and c−Jun. The expressions of these proteins were correlated with the overall survival (OS) and other clinicopathological characteristics of PDAC patients. We obtained 53 PDAC specimens from resections and biopsies. There were significant correlations between the four proteins’ expressions in the PDAC tissues. The expression of the cytoplasmic (aHR = 0.31; 95% CI 0.11–0.90; p = 0.032) or nuclear NF−?B (aHR = 0.22; 95% CI 0.07–0.66; p = 0.007) was independently associated with a better prognosis in the PDAC patients. COX−2, Sp1, and c−Jun showed no significant association with a prognosis in the PDAC patients. The PDAC patients who expressed NF−?B had a better prognosis than the other patients, which suggests that the role of inflammation in PDAC is more complex than previously thought."

"ABSTRAKTelah dilakukan penelitian tentang pengaruh pemberian madu PS (pollen substitute) terhadap gambaran histologi pulau Langerhans pankreas pada mencit (Mus musculus L.) jantan galur DDY yang diinduksi aloksan. Sebanyak 24 ekor mencit dibagi dalam 4 kelompok 6 ulangan, yaitu: kelompok kontrol normal (KK1), kelompok kontrol diabetes (KK2), kelompok perlakuan pemberian madu PS 10% (KP1), dan kelompok perlakuan pemberian madu PS 20% (KP2). Pencekokan madu PS dilakukan setiap hari selama 14 hari berturut-turut. Pada hari ke-15, mencit dikorbankan, organ pankreas diisolasi dan dibuat sediaan histologi menggunakan metode parafin dengan pewarnaan Hematoksilin Eosin (HE). Sediaan diamati secara mikroskopik menggunakan mikroskop cahaya dan mikroproyektor. Data rerata diameter pulau Langerhans mencit dan jumlah sel β pankreas adalah sebagai berikut: KKI (115,03 ± 4,94) µm, (59,47 ± 2,08); KK2 (51,09 ± 8,39) µm, (15,24 ± 2,54); KP1 (106,70 ± 4,75) µm, (40,89 ± 2,33); KP2 (114,24 ± 10,85) µm, (46,78 ± 3,2). Hasil uji LSD (P < 0,05) menunjukkan terdapat perbedaan nyata antara kelompok perlakuan dengan kelompok kontrol KK2. Hal ini berarti bahwa pemberian madu PS (pollen substitute) memengaruhi rerata diameter pulau Langerhans dan jumlah sel β pankreas pada dosis 10% dan 20%.

---

ABSTRACTThe study was undertaken to assess the effect of PS (pollen substitute) honey intake on recovery diameter islet of Langerhans pancreas of alloxan-induced male-DDY mice (Mus musculus L.). Tweenty-four male mice were randomly devided into four groups, consisting of normal control group (KK1), treatment control group (KK2), two treatment groups (KP1 and KP2) which was administered with alloxan and PS honey in concentration of 10% and 20%, respectively. Treatments were carried out orally within 14 consecutive days. The mice were sacrified at day 15 (T15). Histology slides was made with paraffin method and stained with Haematoxyline Eosin (HE) and observed with microscope and microprojector. Mean of diameter of islet of Langerhans and pancreatic cell β number : KKI (115,03 ± 4,94) µm, (59,47 ± 2,08); KK2 (51,09 ±8,39) µm, (15,24 ± 2,54); KP1 (106,70 ± 4,75) µm, (40,89 ± 2,33); KP2 (114,24 ±10,85) µm, (46,78 ± 3,2). Least significant difference (LSD) (P < 0,05%) test showed a significant effect of treatment. The result demonstrated the potential beneficiary effect of PS (pollen substitute) Honey for recovery diameter of islet of Langerhans and pancreatic cell β number in concentration of 10% and 20%."

"ABSTRAKLatar belakang : Fine Needle Aspiration Cytology FNAC adalah teknik yang cepat, murah, dengan komplikasi yang minimal untuk mendiagnosis tumor tulang. FNAC memiliki kapasitas untuk membedakan lesi jinak dan ganas. Namun FNAC memiliki keterbatasan di sisi teknik dan cara interpretasi.Tujuan : mengevaluasi akurasi FNAC sebagai salah satu prosedur preoperasi diagnosis tumor tulang. Metode : Sampel diambil dari arsip rekam medis pasien curiga tumor tulang yang diperiksa dengan FNAC dan histopatologi di Departemen Patologi Anatomi FKUI/RSCM dari tahun 2011 sampai 2014. Uji diagnostik dilakukan untuk mengetahui sensitivitas, spesifisitas, PPV, NPV, dan akurasi dari FNAC. Hasil : Terdapat 78 pasien kasus curiga tumor tulang yang diperiksa dengan FNAC dan Histopatologi di Departemen Patologi Anatomi FKUI/RSCM pada tahun 2011 ndash; 2014. Empat puluh sembilan kasus dilaporkan tumor tulang ganas dengan 5 kasus diskrepansi subtipe ganas dan 20 kasus tumor tulang jinak dengan 1 kasus diskrepansi subtype jinak. Selain itu, terdapat 8 kasus negatif semu dan 1 kasus positif semu. Secara keseluruhan, hasil yang didapatkan adalah sensitivitas 86 , spesifisitas 95.2 , PPV 98 , NPV 71.4 , dan akurasi sebesar 88.5 .Kesimpulan : Penelitian ini menunjukkan bahwa FNAC memiliki kualitas yang baik untuk mendiagnosis tumor tulang, dibuktikan dengan tingginya angka sensitivitas dan spesifisitas 86 dan 95.2 .

---

ABSTRACTBackground Fine Needle Aspiration Cytology FNAC is a rapid, inexpensive, minimum invasive technique with less complication in diagnosing bone neoplasm. FNAC is able to differentiate between neoplasm and non neoplasm cases. However, there are limitations of FNAC technique and interpretation.Aim to evaluate the accuracy of FNAC as one of diagnostic approach in preoperative or diagnosing bone neoplasm.Method Samples were obtained from archives of medical records data of patients who clinically suspected of bone neoplasm and undergo FNAC Histopathology in Anatomical Pathology Department FKUI RSCM from 2011 to 2014. The diagnostic test will be conducted in order to obtain the sensitivity, specificity, PPV, NPV, and accuracy of FNAC.Results There are 78 patients of bone neoplasm were undergo Fine Needle Aspiration Cytology and Histopathology examination from the archives Anatomical Pathology Department in 2011 to 2014. Forty nine cases were reported as malignant bone neoplasm with 5 discrepancy type and 20 cases were benign with 1 discrepancy type. Furthermore, there were 8 false negative cases, and 1 false positive case. The sensitivity, specificity, positive predictive value PPV , negative predictive value NPV , accuracy were 86 . 95.2 . 98 , 71.4 , and 88.5 respectively.Conclusions FNAC shows a good quality as one of diagnostic approach in bone neoplasm as can be seen in a high sensitivity and specificity 86 and 95.2 in this study. "